Karyopharm Therapeutics Inc: Baird cuts to neutral rating; cuts target price to $3 from $15
KPTI•Related News
Lincoln National Corp <LNC.N>: KBW raises target price to $51 from $46
LNC•
CGI Inc <GIB.N>: Jefferies raises target price to $75 from $62
GIB•
Daiichi Sankyo, AstraZeneca Datroway wins EU approval for first-line metastatic TNBC in non-immunotherapy patients
AZN•
Mastercard <MA.N>: RBC Raises Target Price to $642 From $629
MA•
Flowserve Corp <FLS.N>: RBC Raises Target Price to $94 From $91
FLS•